Jessica S Armer1, Lauren Clevenger2, Lauren Z Davis3, Michaela Cuneo1, Premal H Thaker4, Michael J Goodheart5,6, David P Bender5, Laila Dahmoush7, Anil K Sood8, Steven W Cole9, George M Slavich10, Susan K Lutgendorf1,5,6,11. 1. Department of Psychological and Brain Sciences, University of Iowa, Iowa City, Iowa. 2. Department of Psychiatry, University of Iowa, Iowa City, Iowa. 3. Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan. 4. Gynecologic Oncology, Obstetrics and Gynecology, Washington University School of Medicine, St Louis, Missouri. 5. Gynecologic Oncology, Obstetrics and Gynecology, University of Iowa, Iowa City, Iowa. 6. Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa. 7. Department of Pathology, University of Iowa, Iowa City, Iowa. 8. Gyneclogic Oncology, Cancer Biology, and Center for RNA Interference and Noncoding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas. 9. Hematology/Oncology, David Geffen School of Medicine, and the Cousins Center for Psychoneuroimmunology, University of California, Los Angeles, California. 10. Cousins Center for Psychoneuroimmunology and Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA. 11. Department of Urology, University of Iowa, Iowa City, Iowa.
Abstract
BACKGROUND: Patients with ovarian cancer often report elevated anxiety at diagnosis that decreases posttreatment. However, a minority of patients experience sustained anxiety. Few studies have examined risk factors for persistent anxiety or its physiologic sequelae in ovarian cancer. Therefore, the authors investigated associations between prior life events, anxiety, inflammation (plasma levels of interleukin-6), and diurnal cortisol profiles in patients with ovarian cancer during the first year postdiagnosis. METHODS: Participants (n = 337) completed surveys and had blood and salivary sampling prediagnosis, postchemotherapy (6 months), and 12 months after diagnosis. The Life Events and Difficulties Schedule was administered to a patient subset (n = 127) within 1 month of diagnosis. Linear mixed-effects models were used to analyze relations between anxiety and biologic variables over time. Linear regression models assessed whether anxiety trajectories mediated associations between prior stress exposure and biologic variables. Age, chemotherapy at 1 year, and cancer stage were covariates. RESULTS: Decreased anxiety was associated with a more normalized cortisol slope over time (β = 0.092; P = .047). Early life adversity was related to flatter cortisol slopes over time (β = -0.763; P = .002); this relation was partially mediated by anxiety trajectory (P = .046). More danger-related events prediagnosis were associated with sustained anxiety (β = 0.537; P = .019) and flatter cortisol slopes over time (β = -0.243; P = .047); anxiety partially mediated the relation between danger and cortisol slope (P = .037). Neither anxiety nor prior stress exposure was related to levels of interleukin-6. CONCLUSIONS: Because dysregulated cortisol has been related to fatigue, poorer quality of life, and shorter survival in patients with ovarian cancer, those who have prior life events and chronic anxiety during the first year postdiagnosis may be at risk for more negative outcomes. Cancer 2018.
BACKGROUND:Patients with ovarian cancer often report elevated anxiety at diagnosis that decreases posttreatment. However, a minority of patients experience sustained anxiety. Few studies have examined risk factors for persistent anxiety or its physiologic sequelae in ovarian cancer. Therefore, the authors investigated associations between prior life events, anxiety, inflammation (plasma levels of interleukin-6), and diurnal cortisol profiles in patients with ovarian cancer during the first year postdiagnosis. METHODS:Participants (n = 337) completed surveys and had blood and salivary sampling prediagnosis, postchemotherapy (6 months), and 12 months after diagnosis. The Life Events and Difficulties Schedule was administered to a patient subset (n = 127) within 1 month of diagnosis. Linear mixed-effects models were used to analyze relations between anxiety and biologic variables over time. Linear regression models assessed whether anxiety trajectories mediated associations between prior stress exposure and biologic variables. Age, chemotherapy at 1 year, and cancer stage were covariates. RESULTS:Decreased anxiety was associated with a more normalized cortisol slope over time (β = 0.092; P = .047). Early life adversity was related to flatter cortisol slopes over time (β = -0.763; P = .002); this relation was partially mediated by anxiety trajectory (P = .046). More danger-related events prediagnosis were associated with sustained anxiety (β = 0.537; P = .019) and flatter cortisol slopes over time (β = -0.243; P = .047); anxiety partially mediated the relation between danger and cortisol slope (P = .037). Neither anxiety nor prior stress exposure was related to levels of interleukin-6. CONCLUSIONS: Because dysregulated cortisol has been related to fatigue, poorer quality of life, and shorter survival in patients with ovarian cancer, those who have prior life events and chronic anxiety during the first year postdiagnosis may be at risk for more negative outcomes. Cancer 2018.
Authors: Aliza Z Weinrib; Sandra E Sephton; Koen Degeest; Frank Penedo; David Bender; Bridget Zimmerman; Clemens Kirschbaum; Anil K Sood; David M Lubaroff; Susan K Lutgendorf Journal: Cancer Date: 2010-09-15 Impact factor: 6.860
Authors: Aoife O'Donovan; Brian M Hughes; George M Slavich; Lydia Lynch; Marie-Therese Cronin; Cliona O'Farrelly; Kevin M Malone Journal: Brain Behav Immun Date: 2010-03-18 Impact factor: 7.217
Authors: Linda L Carpenter; Cyrena E Gawuga; Audrey R Tyrka; Janet K Lee; George M Anderson; Lawrence H Price Journal: Neuropsychopharmacology Date: 2010-09-29 Impact factor: 7.853
Authors: Sandra E Sephton; Firdaus S Dhabhar; Alex S Keuroghlian; Janine Giese-Davis; Bruce S McEwen; Alexei C Ionan; David Spiegel Journal: Brain Behav Immun Date: 2009-07-28 Impact factor: 7.217
Authors: Andrew Schrepf; Premal H Thaker; Michael J Goodheart; David Bender; George M Slavich; Laila Dahmoush; Frank Penedo; Koen DeGeest; Luis Mendez; David M Lubaroff; Steven W Cole; Anil K Sood; Susan K Lutgendorf Journal: Psychoneuroendocrinology Date: 2015-01-20 Impact factor: 4.905
Authors: Marla S P Cruz; Tercio G Reis; Antoniel C Oliveira; Marluce M Macedo; José de Bessa; Márcio C Oliveira Journal: Health Sci Rep Date: 2022-08-10